Clinical trial
A Single-center, Vehicle-controlled, Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of AZR-MD-001 as Adjunctive Therapy to Conventional Therapeutic Treatment for Meibomian Gland Dysfunction (MGD) or Contact Lens Discomfort (CLD)
Name
SOVS2019-070
Description
SOVS2019-070 is a single-center study of AZR-MD-001 ointment and AZR-MD-001 vehicle in patients with Meibomian Gland Dysfunction (MGD) or Contact Lens Discomfort (CLD).
Trial arms
Trial start
2019-10-04
Estimated PCD
2020-12-11
Trial end
2020-12-11
Status
Completed
Phase
Early phase I
Treatment
AZR-MD-001 Vehicle
AZR-MD-001 is an ophthalmic ointment
Arms:
AZR-MD-001 Vehicle
AZR-MD-001 Active Dose
AZR-MD-001 is an ophthalmic ointment
Arms:
AZR-MD-001 Active Dose
Size
26
Primary endpoint
Primary Efficacy for MGD: Change From Baseline to Month 4 in Meibum Gland Secretion Score (MGS).
Month 4
Primary Efficacy for MGD: Change From Baseline to Month 4 in Meibomian Glands Yielding Liquid Secretion (MGYLS).
Month 4
Eligibility criteria
Inclusion Criteria:
* MGD Patients:
* Evidence of meibomian gland obstruction (based on a meibomian gland secretion (MGS) score of ≤12 for 15 glands of the lower lid) in both eyes at the baseline visit
* Reported dry eye signs and symptoms within the past 3 months
* TBUT \< 10 seconds in both eyes
* CLD Patients:
* Evidence of meibomian gland obstruction (based on a meibomian gland secretion (MGS) score of ≤12 for 15 glands of the lower lid) in both eyes at the baseline visit
* A history of wearing soft contact lenses for at least 6 months
* Wearing of the soft contact lenses for at least 3 weeks before the baseline visit and wore or attempted to wear lenses at least 4 times a week before the baseline visit.
* Symptomatic as defined by an answer of "No" at baseline to the question, "Are you able to comfortably wear your lenses as long as you want?"
* Self-reported history of contact lens dryness/intolerance in the 6 months preceding the baseline visit.
* Baseline CLDEQ-8 score \>12
* Contact lens may be use during the study as long as they are removed 15 minutes before dosing and not reinserted until at least 15 minutes after dosing.
Exclusion Criteria:
* Uncontrolled ocular disease (except for MGD or CLD) or uncontrolled systemic disease
* Patient has glaucoma or ocular hypertension
* Corneal abnormality or disorder that impacts normal spreading of the tear film or corneal integrity
* BCVA worse than 20/40 in either eye at the baseline visit
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 26, 'type': 'ACTUAL'}}
Updated at
2023-01-25
1 organization
1 product
2 indications
Organization
Azura OphthalmicsProduct
AZR-MD-001Indication
Meibomian Gland DysfunctionIndication
Contact Lens Discomfort